A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis

Abstract

The National Institute for Health Research Health Technology Assessment programme.

Allergen immunotherapy for the treatment of allergic rhinitis and/or asthma: an umbrella review

“…Six reviews provided data comparing SLIT with placebo for an outcome of interest, 20,21,24,25,29,33 2 provided data for SCIT versus placebo, 25,29 and 2 provided data comparing SCIT and SLIT. 25,29 Total combined symptom-medication score: Total combined symptom-medication scores were assessed in 3 reviews of SLIT and 1 review of SCIT 20,24,29 ( Figure 2, Table 3).…”

“…25,29 Total combined symptom-medication score: Total combined symptom-medication scores were assessed in 3 reviews of SLIT and 1 review of SCIT 20,24,29 ( Figure 2, Table 3). The 3 reviews reported that SLIT significantly improved total combined symptom-medication score compared to placebo (SMD range -0.94 to -0.31).…”

“…Symptom score: Three reviews reported a significant improvement in symptom score among patients taking SLIT compared to placebo (SMD range -0.49 to -0.28; I 2 = 42%-81%), 21,29,33 and 2 reviews reported improvements with SCIT compared to placebo (SMD range -0.65 to -0.30; I 2 = 57%). 25,29 Two reviews compared the efficacy of SCIT versus SLIT via indirect treatment comparisons.…”

“…25,29 Two reviews compared the efficacy of SCIT versus SLIT via indirect treatment comparisons. 25,29 Dranitsaris and Ellis 25 reported a significant improvement in symptoms for SLIT relative to SCIT (SMD -0.21, 95% CI -0.36 to -0.07).…”

“…25,29 Two reviews compared the efficacy of SCIT versus SLIT via indirect treatment comparisons. 25,29 Dranitsaris and Ellis 25 reported a significant improvement in symptoms for SLIT relative to SCIT (SMD -0.21, 95% CI -0.36 to -0.07). In contrast, Meadows and colleagues 29 reported a significant improvement in symptoms for SCIT relative to SLIT (standard score difference 0.35, 95% credible interval 0.13 to 0.59).…”